Skip to main content

Press Releases and Ad-hoc Announcements

16 November 2017
AH: Heidelberg Pharma AG announces subscription price for new shares and conversion price for convertible bonds from ongoing capital measure
PDF
13 November 2017
PR: Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting
PDF
03 November 2017
AH: Heidelberg Pharma AG plans capital measure to fund its ATAC development programs
PDF
26 October 2017
Heidelberg Pharma AG: Partner RedHill Announces Orphan Drug Designation for MESUPRON
PDF
19 October 2017
PR: WILEX AG successfully completes change of name to Heidelberg Pharma AG
PDF
09 October 2017
AH: WILEX AG announces adjustment of guidance
PDF
09 October 2017
PR: WILEX AG: Interim management statement for the first nine months of 2017
PDF
26 September 2017
PR: WILEX AG: subsidiary Heidelberg Pharma becomes Runner Up in the category Best New Drug Developer at Annual World ADC Award 2017
PDF
20 September 2017
PR: WILEX AG: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit
PDF
13 July 2017
PR: WILEX reports first half 2017 results
PDF
19 June 2017
PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates
PDF
19 June 2017
AH: WILEX AG: Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates
PDF
11 May 2017
PR: WILEX AG successfully completes rights issue
PDF
24 April 2017
AH: WILEX AG plans rights issue using authorised capital
PDF
12 April 2017
PR: WILEX AG: Interim management statement on the first three months of 2017
PDF
30 March 2017
PR: WILEX announces financial figures for the 2016 fiscal year and reports on course of business
PDF
06 February 2017
AH: WILEX AG secures financing commitment from its main shareholder dievini
PDF
25 January 2017
PR: WILEX AG: Subsidiary Heidelberg Pharma Exercises Option on BCMA Antibodies of the Max Delbrück Center and Signs License Agreement
PDF
16 January 2017
AH: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited
PDF
16 January 2017
PR: WILEX Signs Antibody License Agreement with Telix Pharmaceuticals Limited
PDF
26 October 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)
PDF
13 October 2016
PR: WILEX AG: Interim Management Statement on the First Nine Months of 2016
PDF
11 October 2016
AH: WILEX AG secures further financing with shareholder loan based on an existing financing commitment
PDF
27 September 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production
PDF
19 September 2016
PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center
PDF
14 July 2016
PR: WILEX publishes Half-yearly Financial Report
PDF
28 June 2016
PR: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin
PDF
14 June 2016
PM: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pahrma collaborate to create improve cancer therapeutics
PDF
02 June 2016
AH: WILEX AG announces change on the Executive Management Board
PDF
02 June 2016
PR: WILEX AG announces change on the Executive Management Board
PDF